TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

Contributing Editor Jan Ozer recently spoke with Alex Davies, senior analyst at Rethink Technology Research, about Rethink’s new report, “The Media and Entertainment Transcoding Workload and Device ...

Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

This is an edition of The Wonder Reader, a newsletter in which our editors recommend a set of stories to spark your curiosity and fill you with delight. Sign up here to get it every Saturday morning.

One of the joys of parenthood is watching your child reach milestones as they grow to become their own person: first laugh, first roll over, first steps. But one milestone parents really look forward ...

Although software transcoding is accept­able for transcoding most VOD streams and even low-volume live programming, most high-volume live applications need hardware for efficient transcoding, both to ...

TransCode Therapeutics Inc. (NASDAQ:RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead ...

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. Unlock your all-in-one trading dashboard with real-time alerts, ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...